NASDAQ:BTAI BioXcel Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioXcel Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $42.36 -0.68 (-1.58 %) (As of 09/30/2020 11:22 AM ET) Add Compare Share Today's Range$41.83Now: $42.36▼$43.2450-Day Range$37.44MA: $42.58▼$48.4052-Week Range$3.76Now: $42.36▼$71.50Volume2,149 shsAverage Volume611,145 shsMarket Capitalization$946.96 millionP/E RatioN/ADividend YieldN/ABeta1.66 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $95.57, BioXcel Therapeutics has a forecasted upside of 122.1% from its current price of $43.04.Amount of Analyst CoverageBioXcel Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesBioXcel Therapeutics has received 191 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioXcel Therapeutics has received 170 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioXcel Therapeutics has received 52.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote “Outperform” if you believe BTAI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of BioXcel Therapeutics is held by insiders.Percentage Held by Institutions39.74% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($3.38) to ($3.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 28.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTAI Previous Symbol CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone475-238-6837Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book28.43Profitability EPS (Most Recent Fiscal Year)($2.02) Net Income$-32,970,000.00 Net MarginsN/A Return on Equity-114.52% Return on Assets-90.75%Miscellaneous Employees18 Outstanding Shares22,355,000Market Cap$946.96 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $42.36 -0.68 (-1.58 %) (As of 09/30/2020 11:22 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BTAI News and Ratings via Email Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions How has BioXcel Therapeutics' stock been impacted by COVID-19? BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BTAI shares have increased by 43.7% and is now trading at $42.36. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of BioXcel Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioXcel Therapeutics. When is BioXcel Therapeutics' next earnings date? BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for BioXcel Therapeutics. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its earnings results on Friday, August, 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.32. View BioXcel Therapeutics' earnings history. What price target have analysts set for BTAI? 7 brokers have issued 12-month price objectives for BioXcel Therapeutics' stock. Their forecasts range from $24.00 to $175.00. On average, they expect BioXcel Therapeutics' share price to reach $95.57 in the next year. This suggests a possible upside of 125.6% from the stock's current price. View analysts' price targets for BioXcel Therapeutics. Who are some of BioXcel Therapeutics' key competitors? Some companies that are related to BioXcel Therapeutics include Biohaven Pharmaceutical (BHVN), FibroGen (FGEN), Turning Point Therapeutics (TPTX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), Insmed (INSM), Principia Biopharma (PRNB), TG Therapeutics (TGTX), HYPERA S A/S (HYPMY), Global Blood Therapeutics (GBT), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH) and Nektar Therapeutics (NKTR). View all competitors. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), JD.Com (JD), Inseego (INSG), Marvell Technology Group (MRVL), Tesla (TSLA), Advanced Micro Devices (AMD), InVitae (NVTA) and Editas Medicine (EDIT). Who are BioXcel Therapeutics' key executives? BioXcel Therapeutics' management team includes the following people: Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47) When did BioXcel Therapeutics IPO? (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is BioXcel Therapeutics' stock symbol? BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI." How do I buy shares of BioXcel Therapeutics? Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioXcel Therapeutics' stock price today? One share of BTAI stock can currently be purchased for approximately $42.36. How big of a company is BioXcel Therapeutics? BioXcel Therapeutics has a market capitalization of $946.96 million. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe. What is BioXcel Therapeutics' official website? The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com. How can I contact BioXcel Therapeutics? BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
